|
Thu, 12/13/2018 - 17:19 |
PDA calls on DHSC to confirm plans for BREXIT |
PDA |
|
Wed, 11/28/2018 - 06:49 |
Celltrion and Teva Announce FDA Approval of TRUXIMA (rituximab-abbs), a Biosimilar to RITUXAN, for Three Non-Hodgkins Lymphoma Indications |
Teva Pharmaceutical |
|
Tue, 11/27/2018 - 12:13 |
Tevas Generic Version of EpiPen (Epinephrine Injection, USP) Auto-Injector 0.3 mg Now Available in Limited Quantity in the United States |
Teva Pharmaceutical |
|
Tue, 11/27/2018 - 07:08 |
Tevas Generic Epinephrine Injection Now Available in Limited Quantity in the US |
Teva Pharmaceutical |
|
Sat, 10/20/2018 - 23:01 |
Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel |
Teva Pharmaceutical |
|
Thu, 10/18/2018 - 14:52 |
Radio Advertising Bureau, Beasley Media Group, Entercom Communications, iHeartMedia, Inc., Radio One, and the Pennsylvania Broadcasters Association Showcase Radios Local Impact with Radio. Its On! In Philadelphia |
Radio Advertisi... |
|
Wed, 10/10/2018 - 17:07 |
Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar |
Teva Pharmaceutical |
|
Thu, 09/27/2018 - 07:09 |
Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis in the United States |
Teva Pharmaceutical |
|
Fri, 09/14/2018 - 04:35 |
Below is the transcript of a CNBC interview with Michael OGrady, CEO, Northern Trust. The interview was first broadcast on CNBCs Squawk Box Asia on 14 September 2018. |
CNBC |
|
Thu, 09/13/2018 - 20:15 |
Teva Announces U.S. Approval of AJOVY (TM) (fremanezumab-vfrm) Injection |
Teva Pharmaceutical |
|
Thu, 09/13/2018 - 19:55 |
Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults |
Teva Pharmaceutical |
|
Wed, 09/05/2018 - 03:24 |
18,000 people to visit Bristol for University open day |
University of B... |
|
Mon, 08/06/2018 - 06:34 |
Teva Announces Updated Indication and Vial Presentation for GRANIX (tbo-filgrastim) Injection in United States |
Teva Pharmaceutical |
|
Sun, 07/29/2018 - 23:07 |
Decline in working class politicians, shifted Labour towards right wing policy |
UniversityColle... |
|
Tue, 07/17/2018 - 14:37 |
The New York Times Bari Weiss Wins the 2018 Bastiat Prize |
Reason Foundation |
|
Mon, 07/16/2018 - 14:20 |
Rogue Wave Software announces curated open source stacks at OSCON 2018 |
Perforce |
|
Mon, 07/09/2018 - 06:41 |
Teva Announces Launch of a Generic Version of Uceris in the United States |
Teva Pharmaceutical |
|
Wed, 06/13/2018 - 14:54 |
30,000 people to visit Bristol for University open days |
University of B... |
|
Sun, 06/10/2018 - 05:43 |
Fall in trade union membership linked to rising share of income going to top 1% |
IPPR |
|
Wed, 05/23/2018 - 04:21 |
Teva Confirms September PDUFA Date for Fremanezumab |
Teva Pharmaceutical |
|
Mon, 05/07/2018 - 10:04 |
David Meyer to receive University of Minnesota's 2018 Entrepreneur of the Year award |
UniversityofMin... |
|
Thu, 04/12/2018 - 02:44 |
TUC General Secretary urges Theresa May to stand up to 'cliff-edge Brexiteers' |
Ekklesia |
|
Mon, 03/26/2018 - 12:01 |
Teva Announces the Launch of a Generic Version of Lialda in the United States |
Teva Pharmaceutical |
|
Fri, 03/23/2018 - 13:42 |
Teva Announces the Launch of a Generic Version of ALOXI in the United States |
Teva Pharmaceutical |
|
Wed, 03/21/2018 - 03:07 |
Living standards crisis far from over, warns TUC |
Ekklesia |
